HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis.
Sung Soo ParkGi June MinSung-Soo ParkSilvia ParkSung-Eun LeeByung-Sik ChoYoo-Jin KimSeok LeeHee-Je KimChang-Ki MinSeok-Goo ChoJong Wook LeeKi-Seong EomPublished in: Therapeutic advances in hematology (2020)
RIC allo-HCT can be a valid choice providing graft-versus-fibrosis effect for advanced MF patients. However, HLA-mismatched donor and high pre-HCT ferritin level related to fatal hepatic GVHD should be regarded as poor-risk parameters.